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Abstract
Objective To evaluate facial weakness in patients with FSHD to better define clinical signs, and pilot a facial weakness 
severity score.
Methods 87 FSHD patients and 55 controls were video recorded while performing seven facial tasks. The videos were 
assessed by three independent examiners to compile an overview of signs of facial weakness. Next, videos were semi-quan-
titatively assessed using a newly developed 4-point facial weakness score (FWS). This score was evaluated and correlated 
to other FSHD disease characteristics.
Results Patients had lower scores on the total FWS than controls (mean score 43 ± 28, range 4–118, vs 14 ± 9, range 0–35, 
p < 0.001) and on all seven individual facial tasks (all p < 0.001). 54% of patients had FWS scores outside the range of 
controls. Patients had more asymmetry between the left and right side of the face than controls. About 10% of the patients 
had very mild facial weakness. These were mostly males (89%) with longer D4Z4 repeat sizes of 7–9 units. More severe 
facial weakness correlated to more severe overall disease severity and shorter D4Z4 repeat size, but not to disease duration. 
Interobserver agreement for the FWS between three raters was low with a Fleiss Kappa of 0.437.
Conclusion This study provides an overview of the clinical spectrum of facial weakness and its relation to other disease 
characteristics. The 4-point scale we introduced to grade the severity of facial weakness enables correlation of facial weak-
ness to disease characteristics, but is not suited as clinical outcome measure for longitudinal studies.
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Introduction
Facioscapulohumeral muscular dystrophy (FSHD) is a 
progressive inherited muscle disorder. A highly charac-
teristic sign of FSHD is facial weakness that may vary 
between patients from minimal asymmetry to myopathic 
facies [1, 2]. The circular muscles around the eyes and 
mouth (orbicularis oculi and orbicularis oris, respectively) 
and the muscle that raises the corners of the mouth (zygo-
maticus major) are said to be commonly affected [1, 3]. 
A recent study suggests that other facial muscles, like for 
example the m. buccinator, may be affected in FSHD as 
well [2]. The facial weakness results in functional impair-
ments such as difficulties in eating, drinking, speaking, and 
ocular problems, as well as in a reduced ability for facial 
expressions, hindering non-verbal communication.
In spite of its clinical relevance, facial weakness is a 
neglected feature in the consulting room and in research 
on FSHD [4]. Much is known about the specific pattern of 
involvement of the limb muscles, but studies describing 
the clinical characteristics of facial weakness in FSHD 
are scarce. Little is known about the prevalence and (vari-
ability in) the severity of facial weakness, its progression 
over time, relation to other disease characteristics, and the 
consequences of facial weakness for the patients.
This is probably due to the fact that we are lacking 
the clinical approach or tools to structurally assess facial 
weakness and measure changes, and the effect of those 
changes, over time.
To approach the current gap in the availability of tools 
for tracking facial weakness we video recorded faces of 
FSHD patients and controls to better define clinical signs 
of facial weakness to accommodate optimal examination. 
Next, we pilot a newly developed severity score for facial 
weakness to enable comparison between patients, correla-




We included genetically confirmed FSHD patients aged 
18 years or older from a large cross-sectional cohort study 
on FSHD performed at the Neurology department of the 
Radboud University Medical Center (Nijmegen, the Neth-
erlands) from 2014 to 2015 (FSHD-FOCUS study) [5]. 
Study visit companions were invited to participate in the 
non-FSHD control group.
Standard protocol approvals, registrations 
and patient consents
This study was conducted according to the principles of 
the Declaration of Helsinki (version October 2013) and in 
accordance with the Medical Research Involving Human 
Subjects Act (WMO). The study protocol was approved 
by the regional medical ethics committee (CMO Arn-
hem-Nijmegen). Prior to inclusion, all participants signed 
informed consent and if applicable a consent-to-disclose 
form.
Data acquisition
All participants were video recorded while performing clini-
cal exam procedures to elicit facial weakness. Seven differ-
ent facial tasks were performed in random order: closing the 
eyes gently, closing the eyes firmly, raising the eyebrows, 
frowning, pursing the lips, showing the teeth and puffing of 
the cheeks (Fig. 1). All tasks started with a relaxed state of 
facial muscles and ended with the maximal movement possi-
ble. Each movement was performed three times in sequence 
during a session, resulting in twenty-one (seven times three) 
tasks per video (one video per participant).
The videos were recorded with a Canon PowerShot 
SX280 HS camera, which was positioned 70 cm in front of 
the participant. The camera was set to record at a resolution 
of 1920 × 1680 at 60 frames per second.
Assessment of videos
The videos of all patients were independently assessed by 
three researchers (authors TL, SV and KM). Per video the 
researchers listed all clinical signs they noticed that could 
indicate facial weakness. Their assessments were combined 
to compile an overview of all signs noted to better define 
clinical signs of facial weakness.
Next, videos were semi-quantitatively assessed using a 
newly developed 4-point score for facial weakness, ranging 
from normal movements without effort (0) to the inability 
to initiate or perform a movement (3) (Table 1). Members 
of the study team with extensive experience with FSHD 
selected the set of facial movements likely to show changes 
in FSHD patients. Next, four different response options 
were formulated based on observations of clinical features 
in the videos. The assessments were performed indepen-
dently by three experts in facial weakness from different 
disciplines [a mime therapist (CB), a neurologist specialized 
in FSHD (GP) and a speech language pathologist with spe-
cial expertise in neuromuscular diseases (SK)]. All videos 
were cropped to an extend of which they only showed the 
1344 Journal of Neurology (2021) 268:1342–1350
1 3
complete face of participants. The videos were displayed 
to the experts in a randomized order, but the order of facial 
movements of the participants was fixed. Experts applied 
separate scores per task and for the left and the right side 
of the face as weakness is often asymmetrical. The experts 
were blinded for diagnoses of participants (FSHD patient 
or control). The total score of facial weakness was calcu-
lated by the sum of all scores (7 exercises bilaterally) of all 
three observers for one individual and further referred to as 
the ‘facial weakness score (FWS)’. As such, the total score 
ranged from 0 to 126, with higher scores indicating more 
severe weakness.
Clinical severity score
To assess overall disease severity the FSHD evaluation 
score and the clinical severity score by Ricci et al. (‘Ricci 
score’) were used. The FSHD evaluation score is a fifteen 
point scale which grades muscle weakness in six body 
regions with higher scores indicating more severe weak-
ness [6]. The Ricci score is a ten point scale which grades 
overall disease severity with higher scores indicating more 
severe weakness [7].
Facial sparing phenotype
To evaluate whether there were patients with a ‘facial 
sparing’ phenotype we identified patients with weakness 
of the limb muscles (FSHD evaluation score ≥ 6 or a Ricci 
score ≥ 3) whose facial weakness fell well within the range 
of the control group (within the lowest quartile of the FWS 
of the control group).
Fig. 1  Face in rest and facial 
tasks in one of the controls. a 
Resting position; b closing the 
eyes gently; c closing the eyes 
firmly; d raising the eyebrows; 
e frowning; f pursing the lips; g 
showing the teeth and h puffing 
of the cheeks
Table 1  Instructions on the 
scoring sheet for the facial 
weakness score
Score Mouth and forehead Eye closure
0 Complete movement possible Complete eye closure
1 Near complete movement possible Small rim of eyelashes visible on closure
2 Limited movement possible Eyelashes mostly visible on closure
3 Impossible to initiate movement Incomplete eye closure
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Statistical analysis
Descriptive statistics were calculated for all participants. 
Mean and standard deviation are reported unless stated 
otherwise. The Fleiss Kappa value was calculated for the 
reliability of agreement between the three observers. Spear-
men’s rho correlation was used for correlations between 
ordinal scores and Pearson correlation for linear variables. 




Eighty-seven FSHD patients and fifty-five controls were 
included in this study. Baseline characteristics are presented 
in Table 2. Two of the eighty-seven FSHD patients received 
nocturnal non-invasive ventilation.
Overview of signs of facial weakness
An overview of all clinical signs of facial weakness that 
were noted in the video’s is given below to aid in the clinical 
examination of patients. Examples of moderate and severe 
weakness are displayed in Fig. 2.
Upper part of the face
In resting position, subtle weakness of the muscles around 
the eyes can be noted by a difference in palpebral fissure 
height, red conjunctiva when the eyes are dry, and in more 
severe cases hanging of the lower eyelid. Especially older 
patients may have less wrinkles around the eyes and on the 
forehead compared to controls of the same age.
When patients are asked to close their eyes (gently) a 
Bell’s phenomenon may occur, although this also occurred 
in some of the controls. In patients with more severe facial 
weakness there is an inability to fully close the eyes. By 
having the patient close the eyes forcefully more subtle 
weakness can be detected, especially a ‘signe de cils’— an 
inability to bury the eyelashes completely when attempting 
to close the eyes tightly. To compensate for the weakness 
around their eyes, FSHD patients are more likely to move 
their mouth when asked to close their eyes forcefully. Addi-
tionally, their foreheads show less wrinkling, as was also 
the case when asking the patients to raise their eyebrows 
or to frown.
In rest, the position of the eyebrows is asymmetrical in 
part of the patients. This becomes more evident when the 
patient raises the eyebrows or frowns. In contrast, in con-
trols the asymmetry tends to resolve when the patient moves 
the eyebrows. The range of motion of the eyebrows is often 
smaller in FSHD patients compared to controls.
Although we did not specifically test the movement of 
the eyes, we did not see signs suggestive of involvement of 
extraocular muscles. No ptosis was seen.
Lower part of the face
In part of the patients the mouth is asymmetrical in rest 
which can be noticed by a difference in position of the cor-
ners of the mouth, or in more severe cases the philtrum 
is skewed to one side. Severe weakness of the muscles 
around the mouth can cause the lower lip to drop. Asym-
metry becomes more pronounced when a patient performs 
a task like pursing the lips or showing the teeth (raising the 
corners of the mouth). When performing these tasks some 
patients are able to only partly execute the movement, or 
are able to complete the movement but not to maintain the 
final position.
Table 2  Demographic data of 
study population
n/a not applicable
Patients n = 87 Controls n = 55 p value
Male (n, (%)) 51 (58%) 27 (47%) > 0.05
Age in years (mean ± SD [range]) 56.0 ± 15.4 [23–86] 50.9 ± 16.3 [21–87] > 0.05
FSHD type 1
FSHD type 2















Facial weakness score (mean ± SD [range]) 43 ± 28 [4–118] 14 ± 9 [0–35] < 0.001
FSHD evaluation score (mean ± SD [range]) 6.9 ± 4.2 [0–15] n/a
Ricci score (mean ± SD [range]) 5.5 ± 2.8 [0–10] n/a
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Fig. 2  Examples of moderate and severe facial weakness per task (image taken of maximal movement possible)
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When patients attempt to smile, a so called ‘transverse 
smile’ is often seen. Due to the inability to raise the cor-
ners of the mouth, the mouth moves horizontally which may 
look like a grin. In cases of very severe facial weakness 
patients are not able to raise the corners of the mouth at all 
and instead move their lower yaw forward when asked to 
show their teeth.
Facial weakness score
In patients the total score on the FWS ranged from 4 to 
118, compared to a range between 0 and 35 in the con-
trols. Although there was overlap between the scores of the 
patients and the controls, 54% of the patients had scores 
above the upper limit of the control scores (Fig. 3). Patients 
had lower scores than controls on the total FWS (mean score 
43 ± 28 vs 14 ± 9 respectively, p < 0.001) as well as on all the 
seven individual facial tasks (all p < 0.001). There was no 
difference in the severity of the weakness between the upper 
and lower part of the face (no difference in mean scores for 
the tasks concerning weakness in the upper half versus the 
lower half of the face).
Males and females with FSHD had the same degree of 
facial weakness (mean total FWS 38 ± 25 vs 50 ± 30 respec-
tively, p > 0.05).
Patients had more asymmetry between the left and the 
right side of the face than controls (mean absolute difference 
between scores for left and right side of the face 5.1 ± 3.6 vs 
1.7 ± 1.8, p < 0.001). In patients, there was no preference for 
either right- or left-sided facial weakness.
Interobserver agreement for the total FWS score between 
the three experts was generally low with a Fleiss Kappa for 
the total FWS score of 0.437. Although the Fleiss kappa val-
ues varied somewhat between the various facial movement 
tasks, interobserver agreement was poor to moderate for all 
tasks (all Fleiss kappa ≤ 0.52). Collapsing the response cat-
egories from four to three (0–1–2–3 to 0–1–1–2) improved 
interobserver agreement to 0.498. Disagreement between the 
three experts was most pronounced with intermediate sever-
ity of facial weakness (Fig. 4).
Correlation between FWS and FSHD disease 
characteristics
Facial weakness was more severe when overall disease 
severity was more severe on both the FSHD evaluation score 
and Ricci score (ρ 0.561, p < 0.001 and ρ 0.465, p < 0.001 
respectively) and D4Z4 repeat size was shorter (ρ = − 0.507, 
p < 0.01).
Although patients with early onset FSHD (shoulder 
girdle weakness ≤ 10 years of age, n = 6) had more severe 
facial weakness than classical onset patients (mean FWS 
of 91 ± 17 vs 39 ± 25, p < 0.001), there was no correlation 
between disease duration and the degree of facial weak-
ness (r = 0.204, p = 0.085). A weak correlation was found 
between the degree of facial weakness and age in the 
patients (ρ = 0.280, p = 0.009), but not in the control group 
(ρ = − 0.244, p = 0.072).
Facial sparing phenotype
We identified nine out of 87 patients (eight males, age range 
41–73 years) that fulfilled our criteria for a facial sparing 
phenotype. Their FWS results ranged from 7 to 15. All of 
these patients had a D4Z4 repeat array size of five to nine 
units, except for one who was an FSHD2 patient.
In six of these nine patients the experts observed clear, 
though mild, signs of facial weakness (all males, age range 
48–73 years) (Fig. 5). All of these patients had notable 
asymmetry with movements of the mouth, i.e. single sided 


























Fig. 3  Facial weakness score per individual participant ranked per 








































Facial Weakness Score (FWS)
Paent
Control
Fig. 4  Sum of absolute differences in FWS between observers per 
individual. For individuals with moderate weakness the variability 
between observers is higher than for individuals with mild and severe 
weakness
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had signe de cils. One patient had trouble raising his left 
eyebrow.
The other three patients had such minimal signs of facial 
weakness that they could easily go unnoticed upon examina-
tion (2 males, ages 41, 47 and 62 years). One male patient 
only had rightsided signe de cils. The other male patient had 
signe de cils and although he was able to completely raise 
the corners of his mouth, he could not sustain the maximum 
position for more than a second with the left corner of his 
mouth. The female patient had asymmetrical movements of 
the corners of the mouth (right side performed suboptimal) 
when showing the teeth and blowing the cheeks.
Discussion
In this study we systematically assessed facial weakness in 
FSHD in a large group of patients comprising the entire 
clinical spectrum.
Fifty-four percent of the FSHD patients had an FWS 
above the upper limit of the FWS of the control group. This 
indicates that the group of patients with moderate to severe 
weakness can adequately be distinguished from non-FSHD 
controls, but in the group of patients with milder weakness 
assessing facial weakness becomes more complex. Only two 
of all the participants had a completely normal score on the 
FWS. This finding shows that mild signs of facial weakness 
are not necessarily specific for FSHD, but can be seen in the 
general population.
One of the signs of facial weakness that is more spe-
cific for FSHD is left–right asymmetry, as asymmetry was 
more common in patients than controls and patients with 
very mild facial weakness mostly had single sided weak-
ness. More research is required to define other signs of facial 
weakness that can help to reliably discriminate between 
patients and controls.
Some of the controls had relatively high scores (up to 35) 
on the FWS. These scores are probably the result of various 
factors influencing the score. First, despite verbal instruc-
tions some of the controls performed the movements tech-
nically poorly or not with maximum effort, which did not 
seem to be caused by muscle weakness. Second, the experts 
did not know if they were watching a video of a patient or a 
non-FSHD volunteer, which poses a risk of experimenter’s 
bias when scoring the tasks: a tendency of rating values to 
drift towards what is expected by the rater, i.e. a tendency 
to assign higher scores when they suspected that the partici-
pant had FSHD. This is based on the idea that experienced 
researchers evaluate the presence of FSHD in a holistic view 
of the face and movement of the face rather than based on 
individual parts and exercises. Finally, no information was 
collected regarding comorbidities that could have an effect 
on facial muscle function or facial expression in the control 
group.
Approximately 10% of the patients had very mild weak-
ness (within the bottom 75% FWS range of the control 
group). This is line with previous studies reporting a facial 
sparing phenotype in approximately 15% of cases [3, 8]. 
Fig. 5  Examples of subtle signs of facial weakness. a Signe de cils 
right eye (inability to bury the eyelashes completely when attempt-
ing to close the eyes tightly). b Asymmetry in raising the corners of 
the mouth with left corner being raised less high. c Asymmetry when 
pouting the lips due to right sided weakness of the muscles around 
the mouth. d Difficulty puffing the cheeks. Notice the asymmetry and 
the lips being sealed horizontally
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Our study shows, however, that the definition of ‘facial spar-
ing FSHD’ remains challenging. All patients in the study 
that could potentially be classified as having a facial sparing 
phenotype did have mild facial weakness, but this weakness 
fell within the range of what is seen in the control popula-
tion. We identified multiple patients with very subtle signs of 
facial weakness, that were not recognized by the patient and 
could easily be overlooked by an examiner. As such, the term 
‘facial sparing’ should be used with caution in the hands 
of an observer who is not thoroughly familiar with FSHD.
In accordance with the literature, very mild facial weak-
ness was observed in patients with longer repeat array sizes 
of 7–10 D4Z4 units [8–13], which suits the finding that the 
D4Z4 repeat array has a stronger influence of the degree 
of facial weakness than on the upper and lower extremity 
muscle involvement [5].
Although there was no difference in mean FWS between 
males and females, we found that 89% of the patients with 
a facial sparing phenotype was male. This is in concord-
ance with other studies reporting 67–100% of patients being 
male in series (≥ 3 patients) of patients with a facial sparing 
phenotype [8–10, 13–17]. Other sex differences have been 
observed in FSHD, such as a higher proportion of women 
among asymptomatic gene carriers and a higher frequency 
of STIR positive lesions on muscle MRI in males, but these 
are all still pathophysiologically unexplained.
We observed no correlation between the severity of the 
facial weakness and the duration of the disease, although 
there was a weak positive correlation between facial weak-
ness and age in the patients. This suggests that facial weak-
ness in FSHD shows only little progression over time com-
pared to the limb muscles or that progression only occurs 
during a short time interval in life. Longitudinal studies 
should be performed to provide information on progression 
of facial weakness. However, to enable longitudinal stud-
ies, both in the setting of a clinical trial or natural history 
study, an adequate outcome measure for facial weakness is 
required.
The semi-quantitative ‘facial weakness score’ presented 
here allowed us to grade the severity of facial weakness and 
subsequently explore the relation between facial weakness 
and other disease characteristics. The score showed a poor 
agreement between different observers and a range of scores 
in the control group. Therefore, the proposed score in its cur-
rent form serves to make progress in this research field, but 
cannot be used as a clinical outcome measure.
Different explanations for the low interrater agreement 
are possible. First, the experts who assigned the scores 
received limited training to perform the scoring and all 
three had a different background, which may result in 
different interpretations of findings on the facial tasks. 
Second, the risk of experimenter’s bias as mentioned 
above could result in different scores between observers, 
depending on whether they believed they were watching 
a video of a patient or a control. Third, properties of the 
score itself can contribute to a lower reliability. The num-
ber of response options may have been too high to be able 
to discriminate consistently between different answering 
options, although reducing the number of response cat-
egories only mildly improvement the interrater agreement, 
or the phrasing of the response options may have been 
unclear. Although unlikely to resolve the low interrater 
agreement, spontaneous mimical movements and assess-
ment of the face at rest would be of interest to add in future 
work on this topic. Finally, the complexity of the face and 
its movements makes it challenging to develop a (semi)
quantitative scoring system, which is also illustrated by 
the large intra- and interobserver variability when applying 
different scoring systems in studies focused on facial nerve 
dysfunction [18]. This complexity means that a scoring 
system must contain many parameters to provide a reliable 
measure. Finding an easy to implement measure for a com-
plex problem seems a perfect challenge for a computer-
controlled solution like artificial intelligence, thus more 
research is needed to investigate the feasibility of such 
a solution. Future development of a computer-controlled 
system will probably benefit longitudinal evaluation of 
facial weakness greatly.
This study provides an overview of the clinical spec-
trum of facial weakness and its relation to other disease 
characteristics. The task of the developing of an objec-
tive and accurate outcome measure for facial weakness is 
highly challenging and requires more research. The simple 
four point scale we introduced to grade the severity of 
facial weakness, enables correlation of facial weakness 
to disease characteristics, but is not suited as a clinical 
outcome measure for longitudinal studies.
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